Drug Design, Development and Therapy (Mar 2016)
Comments on a meta-analysis and systematic review of the clinicopathological significance of CDH1 in gastric cancer
Abstract
Chao Tu, Lianwen Yuan, Jianping Zhou Department of Geriatric Surgery, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of ChinaWith great interest, we read an article entitled “The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review” by Zeng et al,1 which was published in Drug Design, Development and Therapy in April 2015. In this meta-analysis, the investigators systematically reviewed the studies on correlation between CDH1 hypermethylation and gastric cancer (GC), and concluded that CDH1 hypermethylation levels in GC and adjacent gastric mucosa are both significantly higher when compared with normal gastric mucosa. Meanwhile, CDH1 hypermethylation is found markedly correlated with Helicobacter pylori status. Taken together, CDH1 hypermethylation is positively associated with overall GC risk and the H. pylori-positive GC risk.1 It is a valuable study. Nevertheless, there are several queries that we would like to communicate with the authors.View original article by Zeng et al.
